S
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers
About Synnovation Therapeutics
Synnovation Therapeutics is a precision medicine company that focuses on developing small molecule therapies to treat cancer. These therapies are designed to be highly effective against specific disease targets, which have been thoroughly validated through scientific research. The company leverages its deep expertise in cancer biology and a top-tier medicinal chemistry team to create a diverse range of targeted therapies.
Synnovation Therapeutics operates in the biotechnology and pharmaceutical market, specifically within the oncology (cancer treatment) sector. The company primarily serves patients suffering from various forms of cancer, aiming to improve their lives through innovative treatments.
The business model of Synnovation Therapeutics revolves around the discovery and development of new drugs. They invest heavily in research and development (R&D) to create these small molecule therapies. Once a promising therapy is developed, the company advances it into clinical trials, a crucial step in bringing a new drug to market.
Synnovation Therapeutics makes money by developing these therapies and then either selling them directly, licensing them to larger pharmaceutical companies, or partnering with other organizations to bring the drugs to market. This model allows them to generate revenue while continuing to invest in new research and development projects.
In summary, Synnovation Therapeutics is dedicated to transforming cancer care through patient-focused precision medicine. They are committed to building a skilled and passionate team to drive their mission forward, emphasizing teamwork and diversity within their company culture.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Philadelphia, United States
- Employees
- 51
- Open positions
- 2
- Dealroom signal
- 79.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2024 | $102M | $408M | Nextech Invest · Third Rock Ventures · Cormorant Asset Management · Lilly Asia Ventures | ↗ |
| EARLY VCOther financing | May 2023 | $25M | $100M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Synnovation Therapeutics is 2.3K monthly website visits, down 23.3% over the last three months. Synnovation Therapeutics's team grew 8.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Third Rock Ventures
Nextech Invest
Cormorant Asset Management
Lilly Asia Ventures- SCSirona Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Synnovation Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synnovation Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.